[HTML][HTML] Recent advances in polymeric nanoparticle-encapsulated drugs against intracellular infections

A Sánchez, SP Mejía, J Orozco - Molecules, 2020 - mdpi.com
Polymeric nanocarriers (PNs) have demonstrated to be a promising alternative to treat
intracellular infections. They have outstanding performance in delivering antimicrobials …

[HTML][HTML] Antiviral and antimicrobial nucleoside derivatives: structural features and mechanisms of action

AA Zenchenko, MS Drenichev, IA Il'Icheva… - Molecular biology, 2021 - Springer
The emergence of new viruses and resistant strains of pathogenic microorganisms has
become a powerful stimulus in the search for new drugs. Nucleosides are a promising class …

[HTML][HTML] Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy

SY Cho, DG Lee, HJ Kim - International journal of molecular sciences, 2019 - mdpi.com
Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) is
one of the critical infectious complications related to host immune recovery. The spectrum of …

Efficacy of repurposed antiviral drugs: lessons from COVID-19

MA Martinez - Drug Discovery Today, 2022 - Elsevier
The clinical, social, and economic impacts of the coronavirus disease 2019 (COVID-19)
pandemic, originated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Current therapy for chronic hepatitis C: The role of direct-acting antivirals

G Li, E De Clercq - Antiviral research, 2017 - Elsevier
One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

[HTML][HTML] Approved HIV reverse transcriptase inhibitors in the past decade

G Li, Y Wang, E De Clercq - Acta Pharmaceutica Sinica B, 2022 - Elsevier
HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

Catalytic regioselective acylation of unprotected nucleosides for quick access to COVID and other nucleoside prodrugs

J Lv, J Zou, Y Nong, J Song, T Shen, H Cai, C Mou… - ACS …, 2023 - ACS Publications
Nucleosides have important therapeutic applications that include antiviral activities against
COVID viruses. It is a common strategy to convert one or multiple of the hydroxyl (OH) units …

Pathogenesis‐directed therapy of 2019 novel coronavirus disease

CW Stratton, YW Tang, H Lu - Journal of medical virology, 2021 - Wiley Online Library
The 2019 novel coronavirus disease (COVID‐19) now is considered a global public health
emergency. One of the unprecedented challenges is defining the optimal therapy for those …

[HTML][HTML] Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir

S Jockusch, C Tao, X Li, M Chien, S Kumar… - Scientific reports, 2020 - nature.com
SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a
hundred years. After examining the molecular structures and activities of hepatitis C viral …

An overview of antivirals against monkeypox virus and other orthopoxviruses

J Wang, M Shahed-AI-Mahmud, A Chen… - Journal of medicinal …, 2023 - ACS Publications
The current monkeypox outbreaks during the COVID-19 pandemic have reignited interest in
orthopoxvirus antivirals. Monkeypox belongs to the Orthopoxvirus genus of the Poxviridae …